Both groups concluded that, based upon their unique physiologic activity, efficacy, nonglycemic benefits, and safety profiles, agents which act on the incretin system--the glucagon-like peptide-1 (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors--are important options for the management of patients with T2DM. The gene discussed is GCG; the disease is type 2 diabetes mellitus.